Short-term treatment with diminazene aceturate ameliorates the reduction in kidney ACE2 activity in rats with subtotal nephrectomy

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Velkoska, Elena ^a   Patel, Sheila K ^a   Griggs, Karen ^a   Pickering, Raelene J ^b   Tikellis, Chris ^b   Burrell, Louise M ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; DIMINAZENE ACETURATE; MESSENGER RNA; DIMINAZENE; DIPEPTIDYL CARBOXYPEPTIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYMURIA; EX VIVO STUDY; FEMALE; HYPERTENSION; KIDNEY CORTEX; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY HYPERTROPHY; KIDNEY INJURY; KIDNEY MEDULLA; NEPHRECTOMY; NONHUMAN; RAT; SPRAGUE DAWLEY RAT; SUBTOTAL NEPHRECTOMY; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; INJURIES; KIDNEY; METABOLISM; PHYSIOLOGY; TIME FACTOR; URINE;

RATTUS;

ANIMALS; DIMINAZENE; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; KIDNEY; KIDNEY CORTEX; KIDNEY MEDULLA; NEPHRECTOMY; PEPTIDYL-DIPEPTIDASE A; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; TIME FACTORS;

EID: 84925438687     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0118758     Document Type: Article

References (43)

1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351: 1296-1305. PMID: 15385656
2. Griffin KA, Bidani AK. Progression of renal disease: renoprotective specificity of renin-angiotensin system blockade. Clin J Am Soc Nephrol. 2006; 1: 1054-1065. PMID: 17699327
3. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res. 2000; 87: E1-9. PMID: 10969042
4. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem. 2000; 275: 33238-33243. PMID: 10924499
5. Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A. 2003; 100: 8258-8263. PMID: 12829792
6. Soler MJ, Ye M, Wysocki J, William J, Lloveras J, Batlle D. Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan. Am J Physiol Renal Physiol. 2009; 296: F398-405. doi: 10.1152/ajprenal.90488.2008 PMID: 19004932
7. Ye M, Wysocki J, William J, Soler MJ, Cokic I, Batlle D. Glomerular localization and expression of an-giotensin- converting enzyme 2 and angiotensin-converting enzyme: implications for albuminuria in diabetes. J Am Soc Nephrol. 2006; 17: 3067-3075. PMID: 17021266
8. Velkoska E, Dean RG, Burchill LJ, Levidiotis V, Burrell LM. Reduction in renal ACE2 expression in subtotal nephrectomy is ameliorated with ACE inhibition. Clin Sci (Lond). 2010; 118: 269-279. doi: 10.1042/CS20090318 PMID: 19698082
9. Soler MJ, Wysocki J, Ye M, Lloveras J, Kanwar Y, Batlle D. ACE2 inhibition worsens glomerular injury in association with increased ACE expression in streptozotocin-induced diabetic mice. Kidney Int. 2007; 72: 614-623. PMID: 17579661
10. Wong DW, Oudit GY, Reich H, Kassiri Z, Zhou J, Liu QC, et al. Loss of angiotensin-converting enzyme-2 (ACE2) accelerates diabetic kidney injury. Am J Pathol. 2007; 171: 438-451. PMID: 17600118
11. Cao Z, Burrell LM, Tikkanen I, Bonnet F, Cooper ME, Gilbert RE. Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats. Kidney Int. 2001; 60: 715-721. PMID: 11473654
12. Cao Z, Cooper ME. Role of angiotensin II in tubulointerstitial injury. Semin Nephrol. 2001; 21: 554-562. PMID: 11709803
13. Taal MW, Brenner BM (2008) Adaptation to nephron loss. In: Brenner BM, Rector FC, editors. The Kidney. Philadelphia: Saunders. pp. 783-819.
14. Burrell LM, Burchill L, Dean RG, Griggs K, Patel SK, Velkoska E. Chronic kidney disease: cardiac and renal angiotensin converting enzyme (ACE) 2 expression in rats after subtotal nephrectomy and the effect of ACE inhibition. Exp Physiol. 2012; 97: 477-485. doi: 10.1113/expphysiol.2011.063156 PMID: 22198016
15. Prieto MC, Gonzalez-Villalobos RA, Botros FT, Martin VL, Pagan J, Sato R, et al. Reciprocal changes in renal ACE/Ang II and ACE2/Ang 1-7 are associated with enhanced collecting duct renin in Goldblatt hypertensive rats. Am J Physiol Renal Physiol. 2011; 300: F749-F755. doi: 10.1152/ajprenal.00383.2009 PMID: 21209009
16. da Silveira KD, Pompermayer Bosco KS, Diniz LR, Carmona AK, Cassali GD, Bruna-Romero O, et al. ACE2-angiotensin-(1-7)-Mas axis in renal ischemia/reperfusion injury in rats. Clin Sci (Lond). 2010; 119: 385-394. doi: 10.1042/CS20090554 PMID: 20528771
17. Gupta A, Rhodes GJ, Berg DT, Gerlitz B, Molitoris BA, Grinnell BW. Activated protein C ameliorates LPS-induced acute kidney injury and downregulates renal INOS and angiotensin 2. Am J Physiol Renal Physiol. 2007; 293: F245-254. PMID: 17409278
18. Varagic J, Ahmad S, Nagata S, Ferrario CM. ACE2: Angiotensin II/Angiotensin-(1-7) balance in cardiac and renal injury. Curr Hypertens Rep. 2014; 16: 420. doi: 10.1007/s11906-014-0420-5 PMID: 24510672
19. Zhong J, Guo D, Chen CB, Wang W, Schuster M, Loibner H, et al. Prevention of angiotensin II-mediated renal oxidative stress, inflammation, and fibrosis by angiotensin-converting enzyme 2. Hypertension. 2011; 57: 314-322. doi: 10.1161/HYPERTENSIONAHA.110.164244 PMID: 21189404
20. Oudit GY, Liu GC, Zhong J, Basu R, Chow FL, Zhou J, et al. Human recombinant ACE2 reduces the progression of diabetic nephropathy. Diabetes. 2010; 59: 529-538. doi: 10.2337/db09-1218 PMID: 19934006
21. Hernandez Prada JA, Ferreira AJ, Katovich MJ, Shenoy V, Qi Y, Santos RA, et al. Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension. 2008; 51: 1312-1317. doi: 10.1161/HYPERTENSIONAHA.107.108944 PMID: 18391097
22. Peregrine AS, Mamman M. Pharmacology of diminazene: a review. Acta Trop. 1993; 54: 185-203. PMID: 7902657
23. Kulemina LV, Ostrov DA. Prediction of off-target effects on angiotensin-converting enzyme 2. J Biomol Screen. 2011; 16: 878-885. doi: 10.1177/1087057111413919 PMID: 21859683
24. Murca TM, Moraes PL, Capuruco CA, Santos SH, Melo MB, Santos RA, et al. Oral administration of an angiotensin-converting enzyme 2 activator ameliorates diabetes-induced cardiac dysfunction. Regul Pept. 2012; 177: 107-115. doi: 10.1016/j.regpep.2012.05.093 PMID: 22595130
25. Ibrahim HS, Froemming GR, Omar E, Singh HJ. ACE2 activation by xanthenone prevents leptin-induced increases in blood pressure and proteinuria during pregnancy in Sprague-Dawley rats. Reprod Toxicol. 2014; 49C: 155-161. doi: 10.1016/j.reprotox.2014.08.006 PMID: 25205467
26. Qi Y, Zhang J, Cole-Jeffrey CT, Shenoy V, Espejo A, Hanna M, et al. Diminazene aceturate enhances angiotensin-converting enzyme 2 activity and attenuates ischemia-induced cardiac pathophysiology. Hypertension. 2013; 62: 746-752. doi: 10.1161/HYPERTENSIONAHA.113.01337 PMID: 23959549
27. Shenoy V, Gjymishka A, Yagna J, Qi Y, Afzal A, Rigatto K, et al. Diminazene Attenuates Pulmonary Hypertension and Improves Angiogenic Progenitor Cell Functions in Experimental Models. Am J Respir Crit Care Med. 2013; 187: 648-657. doi: 10.1164/rccm.201205-0880OC PMID: 23370913
28. Burchill L, Velkoska E, Dean RG, Lew RA, Smith AI, Levidiotis V, et al. Acute kidney injury in the rat causes cardiac remodelling and increases angiotensin-converting enzyme 2 expression. Exp Physiol. 2008; 93: 622-630. doi: 10.1113/expphysiol.2007.040386 PMID: 18223026
29. Velkoska E, Dean RG, Griggs K, Burchill LJ, Burrell LM. Angiotensin 1-7 infusion is associated with increased blood pressure and adverse cardiac remodelling in rats with subtotal nephrectomy. Clin Sci (Lond). 2011; 120: 335-345. doi: 10.1042/CS20100280 PMID: 21091432
30. Thomas MC, Tikellis C, Burns WM, Bialkowski K, Cao Z, Coughlan MT, et al. Interactions between renin angiotensin system and advanced glycation in the kidney. J Am Soc Nephrol. 2005; 16: 2976-2984. PMID: 16107577
31. Tikellis C, Cooper ME, Bialkowski K, Johnston CI, Burns WC, Lew RA, et al. Developmental expression of ACE2 in the SHR kidney: A role in hypertension? Kidney Int. 2006; 70: 34-41. PMID: 16710353
32. Thatcher SE, Zhang X, Howatt DA, Yiannikouris F, Gurley SB, Ennis T, et al. Angiotensin-converting enzyme 2 decreases formation and severity of angiotensin II-induced abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2014; 34: 2617-2623. doi: 10.1161/ATVBAHA.114.304613 PMID: 25301841
33. Haber PK, Ye M, Wysocki J, Maier C, Haque SK, Batlle D. Angiotensin-converting enzyme 2-independent action of presumed angiotensin-converting enzyme 2 activators: studies in vivo, ex vivo, and in vitro. Hypertension. 2014; 63: 774-782. doi: 10.1161/HYPERTENSIONAHA.113.02856 PMID: 24446061
34. Raffai G, Khang G, Vanhoutte PM. Angiotensin-(1-7) augments endothelium-dependent relaxations of porcine coronary arteries to bradykinin by inhibiting ACE1. J Cardiovasc Pharmacol. 2014; 63: 453-460. doi: 10.1097/FJC.0000000000000069 PMID: 24390175
35. Wysocki J, Garcia-Halpin L, Ye M, Maier C, Sowers K, Burns KD, et al. Regulation of urinary ACE2 in diabetic mice. Am J Physiol Renal Physiol. 2013; 305: F600-F611. doi: 10.1152/ajprenal.00600.2012 PMID: 23761674
36. Shaltout HA, Westwood BM, Averill DB, Ferrario CM, Figueroa JP, Diz DI, et al. Angiotensin metabolism in renal proximal tubules, urine, and serum of sheep: evidence for ACE2-dependent processing of angiotensin II. Am J Physiol Renal Physiol. 2007; 292: F82-91. PMID: 16896185
37. Mizuiri S, Aoki T, Hemmi H, Arita M, Sakai K, Aikawa A. Urinary ACE2 in patients with CKD. Nephrology (Carlton). 2011; 16: 567-572. doi: 10.1111/j.1440-1797.2011.01467.x PMID: 21457402
38. Lautrette A, Li S, Alili R, Sunnarborg SW, Burtin M, Lee DC, et al. Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach. Nat Med. 2005; 11: 867-874. PMID: 16041383
39. Wang G, Lai FM, Kwan BC, Lai KB, Chow KM, Li PK, et al. Expression of ACE and ACE2 in patients with hypertensive nephrosclerosis. Kidney Blood Press Res. 2011; 34: 141-149. doi: 10.1159/000324521 PMID: 21346373
40. Mizuiri S, Hemmi H, Arita M, Ohashi Y, Tanaka Y, Miyagi M, et al. Expression of ACE and ACE2 in individuals with diabetic kidney disease and healthy controls. Am J Kidney Dis. 2008; 51: 613-623. doi: 10.1053/j.ajkd.2007.11.022 PMID: 18371537
41. Cherney DZ, Xiao F, Zimpelmann J, Har RL, Lai V, Scholey JW, et al. Urinary ACE2 in healthy adults and patients with uncomplicated type 1 diabetes. Can J Physiol Pharmacol. 2014: 1-4. doi: 10.1139/cjpp-2013-0063 PMID: 25615723
42. Park SE, Kim WJ, Park SW, Park JW, Lee N, Park C- Y, et al. High urinary ACE2 concentrations are associated with severity of glucose intolerance and microalbuminuria. Eur J Endocrinol. 2013; 168: 203-210. doi: 10.1530/EJE-12-0782 PMID: 23144053
43. Xiao F, Hiremath S, Knoll G, Zimpelmann J, Srivaratharajah K, Jadhav D, et al. Increased urinary angiotensin-converting enzyme 2 in renal transplant patients with diabetes. PLoS One. 2012; 7: e37649. doi: 10.1371/journal.pone.0037649 PMID: 22629438